Enter multiple symbols separated by commas

Pfizer Inc


  • NEW YORK, May 11- It wasn't long ago that politics, like religious orientation or sexual preference, was a taboo topic in the American workplace. The Washington trade group, which has offices across the street from the White House, helps firms such as Wal-Mart, Halliburton and Lockheed Martin mobilize employees on policy issues important to the companies.

  • NEW YORK, May 6- Drugmakers are building safety "switches" that can be used to turn off powerful cancer therapies known as CAR T cells when they cause life-threatening inflammation or attack healthy tissue. *Bellicum Pharmaceuticals Inc has developed a "switch" by genetically programming a CAR T cell to kill itself when exposed to a drug called rimiducid,...

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...

  • Traders work on the floor of the New York Stock Exchange (NYSE)

    U.S. stocks closed lower, reversing a positive open, as investors weighed higher yields and energy prices ahead of Friday's important jobs report.

  • May 6- The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy. Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5...

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...

  • May 5- Animal health products maker Zoetis Inc said it plans to cut up to a quarter of its workforce and exit nearly 40 percent of its manufacturing plants in its first major restructuring since being spun off from Pfizer Inc two years ago. The restructuring comes a month after activist investor Pershing Square seated their second nominee on Zoetis's board in...

  • A campus brain drain in the US no one talks about Tuesday, 5 May 2015 | 11:00 AM ET
    Immigration reform protesters march to the White House last August.

    Immigration policy discards some of the brightest college grads because they are foreigners, and it's costing our entrepreneurial economy.

  • May 5- Animal health products maker Zoetis Inc said it would reduce operations in Venezuela and consider selling or exiting 10 manufacturing sites over the long term. Ackman's Pershing Square Capital Management was Zoetis's biggest shareholder with an 8.35 percent stake as of April 10, according to Thomson Reuters data. Zoetis, which was spun off from Pfizer...

  • Biotech's boom fuels real estate here Thursday, 30 Apr 2015 | 12:11 PM ET
    Signage sits on display in an atrium at Genzyme Corp.'s headquarters in Cambridge, Massachusetts.

    As biotech has boomed over the last few years, so has real estate in Kendall Square in Cambridge, Massachusetts.

  • NEW YORK/ LONDON, April 30- Pfizer Inc is the mystery bidder for Swedish Orphan Biovitrum AB, the rare disease specialist which disclosed this week that a potential buyer had made a preliminary offer, people with knowledge of the situation said. Sobi did not identify its potential acquirer when it revealed on Monday that it had received an approach, but Biogen and...

  • Trader on the floor of the New York Stock Exchange.

    U.S. stocks traded lower as investors weighed a weaker-than-expected GDP report and earnings reports ahead of the Fed statement release.

  • Dust off the weak economy trade: 5 buys Wednesday, 29 Apr 2015 | 12:23 PM ET
    Traders work the floor of the New York Stock Exchange.

    U.S. GDP figures stalled last quarter, setting up a winning short-term trade in certain sectors and slices of the stock market.

  • Traders work on the floor of the New York Stock Exchange.

    U.S.stocks closed mixed on Tuesday as investors eyed tech earnings and awaited the Federal Reserve's statement on Wednesday.

  • NEW YORK, April 28- A federal judge dismissed claims by former Elan Corp and Wyeth shareholders accusing billionaire investor Steven A. Cohen's SAC Capital Advisors LP of violating federal racketeering law by conducting insider trading in the drugmakers' stocks. District Judge Victor Marrero in Manhattan said the civil claims brought under the Racketeer...

  • US STOCKS-Wall St fall as earnings disappoint Tuesday, 28 Apr 2015 | 10:13 AM ET

    *Merck on track for its best day since January 2014. Apple hit a record high before falling as much as 1.7 percent to $130.33 despite beating Wall Street's revenue and profit forecasts. Merck rose 4.8 percent to $59.85, on track for its best day since January 2014, after its diabetes drug, Januvia, achieved the main goal in a safety study.

  • Apple rose 1.7 percent to $134.87 in premarket trading after beating Wall Street's revenue and profit forecasts as it sold more iPhones in China. Coach shares slumped 5.2 percent to $40.15 after the handbag and accessories maker's quarterly sales fell short of estimates, while Ford Motor fell 1 percent to $15.88 after reporting a profit that was less than...

  • Dollar hits Pfizer; Merck 'blew away' estimates Tuesday, 28 Apr 2015 | 9:04 AM ET
    Tablets of Pfizer Inc.'s Lipitor and Merck & Co.'s Zocor.

    Pfizer reported a 4 percent drop in quarterly revenue, while Merck posted earnings that topped expectations.

  • Janet Yellen speaking on March 18, 2015.

    U.S. stock index futures indicated a flat open on Tuesday ahead of the two-day FOMC meeting, housing data and a busy day of earnings.

  • Innovation driving big pharma: Pro   Tuesday, 28 Apr 2015 | 8:09 AM ET
    Innovation driving big pharma: Pro

    Seamus Fernandez, Leerink Partners, and Barbara Ryan, Clermont Partners, share their thoughts on what's driving big pharma profits.